J
Jennifer J. Kiser
Researcher at University of Montana
Publications - 111
Citations - 4354
Jennifer J. Kiser is an academic researcher from University of Montana. The author has contributed to research in topics: Hepatitis C virus & Sofosbuvir. The author has an hindex of 29, co-authored 100 publications receiving 3563 citations. Previous affiliations of Jennifer J. Kiser include University of Colorado Hospital & University of Cincinnati Academic Health Center.
Papers
More filters
Journal ArticleDOI
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Raymond T. Chung,Marc G. Ghany,Arthur Y. Kim,Kristen M. Marks,Susanna Naggie,Hugo E. Vargas,Andrew Aronsohn,Debika Bhattacharya,Tina Broder,Oluwaseun Falade-Nwulia,Robert J. Fontana,Stuart C. Gordon,Theo Heller,Scott D. Holmberg,Ravi Jhaveri,Maureen M. Jonas,Jennifer J. Kiser,Benjamin P. Linas,Vincent Lo Re,Timothy R. Morgan,Ronald Nahass,Marion G. Peters,K. Rajender Reddy,Andrew Reynolds,John D. Scott,Gloria Searson,Tracy Swan,Norah A. Terrault,Stacey Trooskin,John B. Wong,Kimberly A. Workowski +30 more
TL;DR: This update summarizes the latest release of the HCV guidance and focuses on new or amended recommendations since the previous September 2015 print publication.
Journal ArticleDOI
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure
Jose R Castillo-Mancilla,Jia-Hua Zheng,Joseph E. Rower,Amie L. Meditz,Edward M. Gardner,Julie A. Predhomme,Caitlin Fernandez,Jacob A. Langness,Jennifer J. Kiser,Lane R. Bushman,Peter L. Anderson +10 more
TL;DR: DBSs offer a convenient measure of recent (TFV/FTC) and cumulative ( TFV-DP in RBCs) drug exposure with potential application to adherence monitoring.
Journal ArticleDOI
An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.
Sybil Hosek,Bret J. Rudy,Raphael J. Landovitz,Bill G. Kapogiannis,George K. Siberry,Brandy Rutledge,Nancy Liu,Kathleen Mulligan,Gregory Zimet,Michelle Lally,Kenneth H. Mayer,Peter L. Anderson,Jennifer J. Kiser,James F. Rooney,Craig M. Wilson +14 more
TL;DR: Acceptability of PrEP was high, and most participants achieved protective drug levels during monthly visits, with a noticeable drop-off occurring at week 24, as visit frequency decreased, so did adherence.
Journal ArticleDOI
The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV‐infected Patients
Jennifer J. Kiser,Monica L. Carten,Christina L. Aquilante,Peter L. Anderson,Pamela Wolfe,Tracy King,Thomas Delahunty,Lane R. Bushman,Courtney V. Fletcher +8 more
TL;DR: The effects of lopinavir/ritonavir on tenofovir renal clearance was consistent with a renal interaction between these drugs, and future studies should clarify the exact mechanism and whether there is an increased risk of nephrotoxicity.
Journal ArticleDOI
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection
Peter L. Anderson,Jennifer J. Kiser,Edward M. Gardner,Joseph E. Rower,Amie L. Meditz,Robert M. Grant +5 more
TL;DR: This review identifies important cellular pharmacology considerations for tenofovir and emtricitabine, which include drug penetration into relevant tissues and cell types, race/ethnicity/pharmacogenetics, gender, cellular activation state and appropriate episodic or alternative dosing strategies based on pharmacokinetic principles.